Soros Fund Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-239,823
| Closed | -$26.5M | – | 216 |
|
|
2025
Q1 | $26.5M | Buy |
239,823
+39,823
| +20% | +$4.4M | 0.4% | 55 |
|
|
2024
Q4 | $27.3M | Buy |
200,000
+50,000
| +33% | +$6.83M | 0.41% | 57 |
|
|
2024
Q3 | $17.3M | Sell |
150,000
-44,776
| -23% | -$5.16M | 0.25% | 78 |
|
|
2024
Q2 | $26.8M | Buy |
194,776
+35,000
| +22% | +$4.82M | 0.48% | 43 |
|
|
2024
Q1 | $22M | Sell |
159,776
-25,224
| -14% | -$3.48M | 0.37% | 56 |
|
|
2023
Q4 | $24.4M | Buy |
185,000
+130,000
| +236% | +$17.1M | 0.32% | 54 |
|
|
2023
Q3 | $6.19M | Buy |
+55,000
| New | +$6.19M | 0.09% | 97 |
|
|
2017
Q4 | – | Sell |
-11,300
| Closed | -$692K | – | 241 |
|
|
2017
Q3 | $692K | Buy |
11,300
+6,400
| +131% | +$392K | 0.02% | 131 |
|
|
2017
Q2 | $225K | Buy |
+4,900
| New | +$225K | ﹤0.01% | 174 |
|
|
2016
Q4 | – | Sell |
-11,322
| Closed | -$573K | – | 253 |
|
|
2016
Q3 | $573K | Buy |
+11,322
| New | +$573K | 0.01% | 146 |
|
|
2016
Q2 | – | Sell |
-9,400
| Closed | -$372K | – | 210 |
|
|
2016
Q1 | $372K | Buy |
+9,400
| New | +$372K | 0.01% | 169 |
|
|
2013
Q3 | – | Sell |
-200,000
| Closed | -$2.68M | – | 236 |
|
|
2013
Q2 | $2.68M | Buy |
+200,000
| New | +$2.68M | 0.03% | 145 |
|